XBIO · NASDAQ
Xenetic Biosciences (XBIO) Stock Price & Fundamentals
Xenetic Biosciences (XBIO) closed at $259.08 on Oct 9, 2026, down 0.44% from the previous close of $260.23.
Share price, past year
1Y +0.43%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $259.08 |
| Sep 30, 2026 | $257.76 |
| Aug 31, 2026 | $261.20 |
| Jul 31, 2026 | $268.24 |
| Jun 30, 2026 | $272.19 |
| May 29, 2026 | $259.95 |
| Apr 30, 2026 | $267.69 |
| Mar 31, 2026 | $260.70 |
| Feb 27, 2026 | $256.03 |
| Jan 30, 2026 | $256.94 |
| Dec 31, 2025 | $255.86 |
| Nov 28, 2025 | $264.07 |
| Oct 31, 2025 | $261.91 |
Key statistics
- Market cap
- $607.07M
- P/E (TTM)
- —
- EPS (TTM)
- −$1.15
- Revenue (TTM)
- $3.26M
- Net income (TTM)
- −$2.48M
- Shares outstanding
- 2.3M
- Dividend yield
- —
- 52-week range
- $251.68 – $277.38
Xenetic Biosciences's market cap is $607.07M, based on a share price of $259.08 and 2.3M shares outstanding as of Jun 30, 2026.
Financials
Xenetic Biosciences reported revenue of $2.98M for fiscal 2025, up 19.04% from fiscal 2024.
Xenetic Biosciences reported a net loss of $2.68M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $2.98M | +19.0% | −$2.68M | −90.1% | −$1.58 | — |
| FY2024ended Dec 31, 2024 | $2.50M | −1.6% | −$3.96M | −158.4% | −$2.57 | — |
| FY2023ended Dec 31, 2023 | $2.54M | +48.8% | −$4.13M | −162.8% | −$2.71 | — |
| FY2022ended Dec 31, 2022 | $1.71M | +47.1% | −$6.55M | −383.9% | −$4.61 | — |
| FY2021ended Dec 31, 2021 | $1.16M | +165.6% | −$5.65M | −486.4% | −$0.55 | — |
| FY2020ended Dec 31, 2020 | $436.94K | +2,460.3% | −$10.89M | −2,493.1% | −$1.70 | — |
| FY2019ended Dec 31, 2019 | $17.07K | — | −$12.78M | −74,856.6% | −$6.33 | — |
| FY2018ended Dec 31, 2018 | $0.00 | −100.0% | −$7.30M | — | −$9.66 | −$6.46M |
| FY2017ended Dec 31, 2017 | $7.59M | +152.8% | −$3.60M | −47.4% | −$0.41 | $1.48M |
| FY2016ended Dec 31, 2016 | $3.00M | — | −$54.21M | −1,806.9% | −$7.84 | −$8.80M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $660.60K | −$929.70K | −$0.41 |
| Q1 FY2026ended Mar 31, 2026 | $806.92K | −$456.38K | −$0.20 |
| Q4 FY2025ended Dec 31, 2025 | $766.30K | −$579.08K | −$0.21 |
| Q3 FY2025ended Sep 30, 2025 | $1.03M | −$509.94K | −$0.33 |
| Q2 FY2025ended Jun 30, 2025 | $589.90K | −$688.70K | −$0.45 |
| Q1 FY2025ended Mar 31, 2025 | $593.26K | −$903.14K | −$0.59 |
| Q4 FY2024ended Dec 31, 2024 | $648.82K | −$1.05M | −$0.68 |
| Q3 FY2024ended Sep 30, 2024 | $614.24K | −$436.67K | −$0.28 |
Company profile
- Name
- Xenetic Biosciences, Inc.
- Ticker
- XBIO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 945 Concord St., Framingham, MA 01701
- Incorporated in
- NV
- Fiscal year ends
- December
- SEC CIK
- 0001534525
Recent SEC filings
- Sep 23, 2026
- Sep 16, 2026
- Aug 7, 2026
- Aug 6, 2026
- May 13, 2026
- May 12, 2026
- Apr 24, 2026
- Apr 24, 2026
Frequently asked questions
What is Xenetic Biosciences's stock price?
Xenetic Biosciences (XBIO) closed at $259.08 on Oct 9, 2026, down 0.44% from the previous close of $260.23.
What is Xenetic Biosciences's market cap?
Xenetic Biosciences's market cap is $607.07M, based on a share price of $259.08 and 2.3M shares outstanding as of Jun 30, 2026.
How much revenue does Xenetic Biosciences make?
Xenetic Biosciences reported revenue of $2.98M for fiscal 2025, up 19.04% from fiscal 2024.
Does Xenetic Biosciences pay a dividend?
Xenetic Biosciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Xenetic Biosciences, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures